Compare OMDA & OPK Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | OMDA | OPK |
|---|---|---|
| Founded | 2011 | 2006 |
| Country | United States | United States |
| Employees | 946 | N/A |
| Industry | Medical/Nursing Services | Biotechnology: Pharmaceutical Preparations |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.2B | 1.0B |
| IPO Year | 2025 | 2011 |
| Metric | OMDA | OPK |
|---|---|---|
| Price | $18.86 | $1.64 |
| Analyst Decision | Buy | Buy |
| Analyst Count | 12 | 6 |
| Target Price | ★ $28.42 | $4.15 |
| AVG Volume (30 Days) | 1.0M | ★ 3.6M |
| Earning Date | 11-05-2026 | 11-06-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 94.27 | N/A |
| EPS | ★ 0.04 | N/A |
| Revenue | $260,210,000.00 | ★ $606,879,000.00 |
| Revenue This Year | $30.17 | N/A |
| Revenue Next Year | $20.40 | N/A |
| P/E Ratio | $474.75 | ★ N/A |
| Revenue Growth | ★ 53.24 | N/A |
| 52 Week Low | $10.28 | $0.98 |
| 52 Week High | $26.92 | $1.77 |
| Indicator | OMDA | OPK |
|---|---|---|
| Relative Strength Index (RSI) | 43.74 | 57.99 |
| Support Level | $18.74 | $1.10 |
| Resistance Level | $21.76 | $1.75 |
| Average True Range (ATR) | 1.07 | 0.10 |
| MACD | -0.02 | 0.02 |
| Stochastic Oscillator | 30.97 | 72.34 |
Omada Health Inc empowers individuals to make lasting health changes through personalized, virtual care between doctor's visits. The integrated platform of the company supports members with cardiometabolic conditions like prediabetes, diabetes, hypertension, musculoskeletal issues, and behavioral health needs. The company's specialized care tracks also assist members using GLP-1 medications. The company delivers measurable health outcomes and value for employers, health plans, health systems, and pharmacy benefit managers.
OPKO Health Inc is a diversified biotechnology company that operates pharmaceutical and diagnostic development programs. Its segments include pharmaceutical and diagnostics. The Pharmaceutical segment consists of its pharmaceutical operations in Chile, Mexico, Ireland, Israel, Spain, Ecuador, France, the United States, and its pharmaceutical research and development operations. The Diagnostics segment consists of clinical and genomics laboratory operations through BioReference and point-of-care operations. It generates the majority of its revenue from the Diagnostics segment.